Dabrafenib plus trametinib combination therapy in pediatric patients with BRAF V600-mutant low-grade glioma: Safety and efficacy results.

被引：0
|
作者：
Geoerger, Birgit
Bouffet, Eric
Whitlock, James A.
Moertel, Christopher L.
Hargrave, Darren R.
Aerts, Isabelle
Cohen, Kenneth J.
Kilburn, Lindsay Baker
Wright, Karen D.
Choi, Jeea
Gasal, Eduard
Russo, Mark W.
Fox, Elizabeth
机构：
[1] Univ Paris Saclay, Gustave Roussy Canc Ctr, Villejuif, France
[2] Univ Toronto, Hosp Sick Children, Toronto, ON, Canada
[3] Univ Minnesota, Masonic Childrens Hosp, Minneapolis, MN USA
[4] UCL Great Ormond St Inst Child Hlth, London, England
[5] PSL Res Univ, Inst Curie, Oncol Ctr SIREDO, Paris, France
[6] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[7] Childrens Natl Hosp, Washington, DC USA
[8] Boston Childrens Canc & Blood Disorders Ctr, Dana Farber Canc Inst, Boston, MA USA
[9] Novartis Pharmaceut, E Hanover, NJ USA
[10] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10506
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma
    Bouffet, Eric
    Geoerger, Birgit
    Moertel, Christopher
    Whitlock, James A.
    Aerts, Isabelle
    Hargrave, Darren
    Osterloh, Lisa
    Tan, Eugene
    Choi, Jeea
    Russo, Mark
    Fox, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 664 - +
  • [2] SAFETY AND EFFICACY OF TRAMETINIB (T) MONOTHERAPY AND DABRAFENIB plus TRAMETINIB (D plus T) COMBINATION THERAPY IN PEDIATRIC PATIENTS WITH BRAF V600-MUTANT LOW-GRADE GLIOMA (LGG)
    Bouffet, Eric
    Whitlock, James A.
    Moertel, Christopher
    Geoerger, Birgit
    Aerts, Isabelle
    Hargrave, Darren
    Cohen, Kenneth J.
    Kilburn, Lindsay B.
    Upadhyaya, Santhosh A.
    Wetmore, Cynthia
    Wright, Karen D.
    Choi, Jeea
    Gasal, Eduard
    Russo, Mark W.
    Fox, Elizabeth
    NEURO-ONCOLOGY, 2020, 22 : 375 - 375
  • [3] Efficacy and safety of dabrafenib as a potential treatment for pediatric patients with BRAF V600-mutant low-grade glioma
    Pamula, M. J.
    Santoso, K. J. A.
    Kurniawan, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1403 - S1403
  • [4] Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600-mutant relapsed refractory low-grade glioma.
    Kieran, Mark W.
    Bouffet, Eric
    Broniscer, Alberto
    Cohen, Kenneth J.
    Geoerger, Birgit
    Hansford, Jordan R.
    Hingorani, Pooja
    Aerts, Isabelle
    Andre, Nicolas
    Bertozzi-Salamon, Anne-Isabelle
    Dunkel, Ira J.
    Hummel, Trent Ryan
    Leary, Sarah
    Moreno, Lucas
    Russo, Mark W.
    Tseng, Lillian
    Dasgupta, Kohinoor
    Nebot, Noelia
    Whitlock, James
    Hargrave, Darren R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma
    Hargrave, Darren R.
    Terashima, Keita
    Hara, Junichi
    Kordes, Uwe R.
    Upadhyaya, Santhosh A.
    Sahm, Felix
    Bouffet, Eric
    Packer, Roger J.
    Witt, Olaf
    Sandalic, Larissa
    Kieloch, Agnieszka
    Russo, Mark
    Cohen, Kenneth J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (33) : 5174 - +
  • [6] EFFICACY AND SAFETY OF DABRAFENIB plus TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E-MUTATED LOW-GRADE GLIOMA (LGG)
    Wen, Patrick
    De Greve, Jacques
    Mason, Warren
    Hofheinz, Ralf-Dieter
    Dietrich, Sascha
    de Vos, Filip
    van den Bent, Martin
    Mookerjee, Bijoyesh
    Boran, Aislyn
    Burgess, Paul
    Rangwala, Fatima
    Gazzah, Anas
    NEURO-ONCOLOGY, 2018, 20 : 238 - 238
  • [7] Phase II open-label, global study evaluating dabrafenib in combination with trametinib in pediatric patients with BRAF V600-mutant high-grade glioma (HGG) or low-grade glioma (LGG)
    Hargrave, D.
    Witt, O.
    Cohen, K.
    Packer, R.
    Lissat, A.
    Kordes, U.
    Laetsch, T. W.
    Hoffman, L.
    Lassaletta, A.
    Gerber, N. U.
    Gilheeney, S.
    Holm, S.
    Kramm, C.
    Sumerauer, D.
    Reitmann, C.
    Russo, M. W.
    Bouffet, E.
    ANNALS OF ONCOLOGY, 2018, 29 : 132 - 132
  • [8] SAFETY AND EFFICACY OF DUAL THERAPY WITH DABRAFENIB AND TRAMETINIB IN AN INFANT WITH BRAF V600E MUTANT INOPERABLE LOW GRADE GLIOMA
    Green, Sage
    Walter, Andrew
    Piatt, Joseph
    Kaur, Gurcharanjeet
    NEURO-ONCOLOGY, 2021, 23 : 34 - 34
  • [9] Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG).
    Subbiah, Vivek
    Stein, Alexander
    van den Bent, Martin
    Wick, Antje
    de Vos, Filip Y.
    von Bubnoff, Nikolas
    van Linde, Myra E.
    Lai, Albert
    Prager, Gerald W.
    Campone, Mario
    Fasolo, Angelica
    Lopez-Martin, Jose A.
    Kim, Tae Min
    Hofheinz, Ralf-Dieter
    Blay, Jean-Yves
    Cho, Daniel C.
    Gazzah, Anas
    Pouessel, Damien
    Yachnin, Jeffrey
    Boran, Aislyn
    Burgess, Paul
    Ilankumaran, Palanichamy
    Gasal, Eduard
    Wen, Patrick Y.
    CANCER RESEARCH, 2021, 81 (13)
  • [10] The first study of dabrafenib in pediatric patients with BRAF V600-mutant relapsed or refractory low-grade gliomas
    Kieran, M. W.
    Bouffet, E.
    Tabori, U.
    Broniscer, A.
    Cohen, K.
    Hansford, J.
    Geoerger, B.
    Hingorani, P.
    Dunkel, I.
    Russo, M.
    Tseng, L.
    Liu, Q.
    Nebot, N.
    Whitlock, J.
    Hargrave, D.
    ANNALS OF ONCOLOGY, 2016, 27
12345